Lilly's Taltz Gets Closer To A Level Playing Field With Novartis' Cosentyx
Executive Summary
Lilly reported positive results for Taltz in a second Phase III study in ankylosing spondylitis and plans to file for FDA approval this year, which would give the IL-17A inhibitor a label similar to its rival Cosentyx, for which Novartis is working hard to build, maintain and grow market share.
You may also be interested in...
Lilly May Face Q2 Blues As Prior Stocking Takes Effect
Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.
Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes
Taltz has sailed through the latest trial in Lilly’s COAST program, in non-radiographic axial spondyloarthritis, but choppy waters may be ahead; meanwhile, Lilly signs an immunology deal with Avidity Biosciences.
Five-Year Data Consolidate Cosentyx Benefits
Cosentyx sales are growing at an impressive rate – up 37% in Q3 – and strong five-year safety and efficacy data in psoriatic arthritis and ankylosing spondylitis is likely to drive that growth even higher.